Caladrius Biosciences, Inc. (NASDAQ: CLBS) Director buys $ 30,068.65 in shares
Caladrius Biosciences, Inc. (NASDAQ: CLBS) director Steven S. Myers acquired 33,785 shares of the company in a transaction dated Wednesday, December 8. The shares were purchased at an average price of $ 0.89 per share, for a total transaction of $ 30,068.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
CLBS shares traded down $ 0.01 during trading hours on Friday, reaching $ 0.89. The stock had a trading volume of 210,698 shares, compared to its average volume of 2,047,451. The company has a market capitalization of $ 53.18 million, a P / E ratio of -1.30 and a beta of 1.02. The company’s fifty-day simple moving average is $ 1.07 and its 200-day simple moving average is $ 1.28. Caladrius Biosciences, Inc. has a 12-month low of $ 0.82 and a 12-month high of $ 4.89.
Caladrius Biosciences (NASDAQ: CLBS) last released its results on Thursday, November 4. The biotech company reported ($ 0.12) earnings per share for the quarter, beating the consensus estimate of ($ 0.13) by $ 0.01. During the same period of the previous year, the company made earnings per share ($ 0.29). As a group, sell-side analysts expect Caladrius Biosciences, Inc. to post EPS of -0.55 for the current year.
Several institutional investors and hedge funds have recently changed their holdings to CLBS. Morgan Stanley increased its position in Caladrius Biosciences shares by 533.0% in the 1st quarter. Morgan Stanley now owns 70,537 shares of the biotech company valued at $ 137,000 after purchasing an additional 59,393 shares during the period. Millennium Management LLC acquired a new position in Caladrius Biosciences during the first quarter for a value of approximately $ 86,000. Geode Capital Management LLC strengthened its position in Caladrius Biosciences by 17.1% in the second quarter. Geode Capital Management LLC now owns 372,530 shares of the biotech company valued at $ 599,000 after purchasing an additional 54,377 shares during the period. Renaissance Technologies LLC increased its position in Caladrius Biosciences by 7.0% in the second quarter. Renaissance Technologies LLC now owns 1,562,832 shares of the biotech company valued at $ 2,516,000 after purchasing an additional 102,677 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in Caladrius Biosciences in the second quarter for a value of approximately $ 87,000. 10.52% of the shares are currently held by institutional investors and hedge funds.
Several equity research analysts recently published reports on the company. Zacks Investment Research downgraded Caladrius Biosciences from a âbuyâ rating to a âkeepâ rating in a report released on Wednesday, November 10. HC Wainwright lowered its price target on Caladrius Biosciences from $ 10.00 to $ 8.00 and set a âbuyâ rating on the stock in a report released on Friday, November 5th.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a biopharmaceutical company dedicated to the development of cell therapies for certain cardiovascular and autoimmune diseases. Its product pipeline includes CLBS12, CLBS14, CLBS16 and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, New Jersey.
See also: Explanation of the average daily trading volume
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [emailÂ protected]
Should you invest $ 1,000 in Caladrius Biosciences now?
Before you consider Caladrius Biosciences, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes over … and Caladrius Biosciences was not on the list.
Although Caladrius Biosciences currently has a âBuyâ rating among analysts, top-rated analysts believe these five stocks are better bids.
See the 5 actions here